Navigation Links
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
Date:9/21/2009

THOUSAND OAKS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA).

For the primary endpoint of this study, the median time to first on-study skeletal related event (SRE) (fracture, radiation to bone, surgery to bone, or spinal cord compression) was 20.6 months for those patients receiving denosumab and 16.3 months for those patients receiving Zometa (hazard ratio 0.84, 95 percent CI: 0.71-0.98), which is statistically significant for non-inferiority (p=0.0007). Although numerically greater, the delay in the time to first SRE associated with denosumab was not statistically superior compared to Zometa based upon the statistical testing strategy (adjusted p=0.06) (secondary endpoint). The time to first-and-subsequent SRE was also numerically greater but not statistically superior compared to Zometa (hazard ratio 0.90, 95 percent CI: 0.77-1.04, p=0.14) (secondary endpoint).

"It is encouraging to see denosumab's efficacy in this broad cancer population. There is no need for renal monitoring or dose adjustments due to renal impairment," said David Henry, M.D., clinical professor of Medicine, Pennsylvania Hospital, Philadelphia, PA, United States of America. "Furthermore, the positive results of this study, combined with the convenience of a monthly subcutaneous injection and without the fl
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014   Regulus Therapeutics Inc ... company leading the discovery and development of innovative ... its ATHENA natural history of disease study in ... disease with no approved therapy. The ATHENA study ... renal function markers such as Glomerular Filtration Rate ...
(Date:9/18/2014)... and ROCKVILLE, Md. , ... SPPI ), a biotechnology company with fully integrated ... in hematology and oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ...
(Date:9/18/2014)... Sept. 18, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that the Company,s ... Geert Cauwenbergh , will present at the ... on Wednesday, September 24, 2014 at 11:20 ...
Breaking Medicine Technology:Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... 2011 On Sunday, August 21, veterinary cardiologists are ... the Mobile Dog Heart Health Tour will stop with ... examinations at Peters Park Dog Run. (Photo: ... free heart health screenings, veterinarians will be available to ...
... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... it has finalized a previously disclosed Equipment Financing ... $10 million in available funding. This agreement will ... finance the automated assembly line now manufacturing the ...
Cached Medicine Technology:Free Dog Heart Health Screenings Available August 21 in Boston 2Unilife Signs $10 Million Equipment Financing Agreement 2Unilife Signs $10 Million Equipment Financing Agreement 3Unilife Signs $10 Million Equipment Financing Agreement 4
(Date:9/18/2014)... that elderly men should not be routinely screened for ... a new study led by researchers at Henry Ford ... in JAMA Internal Medicine , focused on the ... for prostate cancer., "We found that the effect of ... men in particular has been minimal at best," says ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 ChopChop ... Bill Yosses and Yonah Kalikow, 10-year-old Massachusetts’s winner of the ... twist on hummus, the classic Middle Eastern bean dip. Watch ... stage how kids can create their own healthy dips at ... at the third annual Let’s Talk About Food Festival ...
(Date:9/18/2014)... Technology Association of Georgia in collaboration with TAG ... Savvy Awards this week at a special ceremony held ... Downtown Atlanta. The event celebrates Georgia’s best and brightest ... with the 2014 TAG Social Savvy People’s Choice Award ... 6 other award categories: , ,     UPS ...
(Date:9/18/2014)... 18, 2014 Once again, Hickman’s Family ... restaurants around the Valley to celebrate PJs & Eggs. ... Egg Day”: Friday, October 10, 2014. The “breakfast for ... to benefit Arizona’s Children Association (AzCA) foster care programs ... at each participating restaurant on October 10 are invited ...
(Date:9/18/2014)... cancer-hampering molecules show promise in slowing the progression ... often linked to asbestos. Scientists from Case Western ... demonstrate that application of curcumin, a derivative of ... of a protein inhibitor known to combat the ... the Aug. 14 online edition Clinical Cancer ...
Breaking Medicine News(10 mins):Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 2Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 3Health News:Winners Honored at 2014 TAG Social Savvy Awards 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 3Health News:October 10th Is 6th Annual PJs & Eggs: Hickman’s Family Farms and Breakfast Restaurants Partner to Benefit Arizona Foster Children 2Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 2Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 3
... The most common form of thalassaemia disease may ... ,Hemoglobin E ? thalassaemia—the commonest form of ... without transfusion in many patients, suggests a research ... The Lancet. The authors state that the finding ...
... of researchers at Vienna University have said they are ... it will be effective against lung cancer//. , ... much more research was still needed before the new ... statement Tuesday. , ,"In fact it's a paradox," ...
... to complex problems lies at hand but that is the ... new anti obesity drug//. A weight control protein with a ... content may yield new approaches for treating obesity and type ... particular variants of the protein SH2-B might underlie obesity in ...
... found a new protein which may be responsible for the ... is known as MSF protein is produced in high quantity ... produced may be responsible for the severity of disease progression. ... protein, the scientists are looking into the properties of these ...
... vulnerable to suffer from the dreaded disease of multiple ... risk//. ,According to the most complete genetic study ... from Vanderbilt University in Nashville, Tennessee at the 130th ... Diego, a cluster of genes on chromosome six is ...
... research report published in the latest issue of Archives ... ready to deal with the threat of bio-terrorism that ... ,More than one-half of 631 physicians tested were ... likely to be used by bio-terrorists. However, test scores ...
Cached Medicine News:Health News:Flu Vaccine Can Be Used To Treat Lung Cancer 2Health News:An Answer To Obesity: Weight Control Protein 2
Caspar Curette, 250 mm, 10"....
Bone Curette, 160 mm...
Bone Curette, 145 mm...
Bone Currettes...
Medicine Products: